Trials / Completed
CompletedNCT02518139
A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
A Phase 3, 52-week, Randomized, Active-Controlled Parallel Group Study to Evaluate the Safety and Tolerability of Nebulized TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,060 (actual)
- Sponsor
- Mylan Inc. · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to measure the safety and tolerability of TD 4208, an investigational drug being developed to treat people with moderate to very severe COPD, compared to tiotropium.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TD-4208 | Subjects receiving TD-4208 are blinded to one of two doses of 4208. |
| DRUG | Tiotropium | There is not a placebo, there is an active comparator (Tiotropium) arm. |
Timeline
- Start date
- 2015-09-01
- Primary completion
- 2017-06-01
- Completion
- 2017-06-01
- First posted
- 2015-08-07
- Last updated
- 2022-02-24
- Results posted
- 2018-12-31
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02518139. Inclusion in this directory is not an endorsement.